Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry
Objective To assess the impact of new-onset atrial fibrillation (AF) on patients hospitalized with coronavirus disease 2019 (COVID-19). Methods Multicenter and retrospective study that included subjects >55 years hospitalized with COVID-19 from March to October 2020 in Spanish hospitals. Patients...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-10-01
|
| Series: | Clinical and Applied Thrombosis/Hemostasis |
| Online Access: | https://doi.org/10.1177/10760296231208440 |
| _version_ | 1827779039609225216 |
|---|---|
| author | Juan José Cerezo Manchado MD, PhD Teodoro Iturbe Hernández MD, PhD María del Carmen Martínez Pacheco MSc, RN Ignacio Gil Ortega MD, PhD Desirée Campoy MD Tania Canals Pernas MD Laia Martinez Serra MD Katia Jessica Flores Aparco MD Cesar Andres Velasquez Escandon MD Luis García de Guadiana-Romualdo MD, PhD Antonio Martinez Frances MD Pavel Olivera MD |
| author_facet | Juan José Cerezo Manchado MD, PhD Teodoro Iturbe Hernández MD, PhD María del Carmen Martínez Pacheco MSc, RN Ignacio Gil Ortega MD, PhD Desirée Campoy MD Tania Canals Pernas MD Laia Martinez Serra MD Katia Jessica Flores Aparco MD Cesar Andres Velasquez Escandon MD Luis García de Guadiana-Romualdo MD, PhD Antonio Martinez Frances MD Pavel Olivera MD |
| author_sort | Juan José Cerezo Manchado MD, PhD |
| collection | DOAJ |
| description | Objective To assess the impact of new-onset atrial fibrillation (AF) on patients hospitalized with coronavirus disease 2019 (COVID-19). Methods Multicenter and retrospective study that included subjects >55 years hospitalized with COVID-19 from March to October 2020 in Spanish hospitals. Patients were divided into 3 groups (no AF, new-onset AF, and preexisting AF) and followed-up to 90 days. Results A total of 668 patients were included, of whom 162 (24.3%) had no AF, 107 (16.0%) new-onset AF and 399 (59.7%) preexisting AF. Compared to patients without AF, those patients with new-onset AF were older and had more comorbidities, but without differences with preexisting AF. During hospitalization, in the univariate analysis, compared to patients without AF, major bleeding and cardiovascular mortality were more frequent in patients with new-onset AF (10.3% vs 0.6%; P < .001; 2.8% vs 0.6%; P = .025, respectively), with a trend toward more stroke (1.9% vs 0%; P = .085). Outcomes were similar between AF groups, but the length of stay was greater in preexisting AF patients. Among patients with new-onset AF taking reduced doses of anticoagulant treatment was associated with higher risks of stroke and major bleeding. Conclusions In COVID-19 hospitalized patients, new-onset AF may be associated with worse outcomes, but influenced by the dose of anticoagulants. |
| first_indexed | 2024-03-11T14:44:32Z |
| format | Article |
| id | doaj.art-9c05d01011484402be04f4e7c378f244 |
| institution | Directory Open Access Journal |
| issn | 1938-2723 |
| language | English |
| last_indexed | 2024-03-11T14:44:32Z |
| publishDate | 2023-10-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical and Applied Thrombosis/Hemostasis |
| spelling | doaj.art-9c05d01011484402be04f4e7c378f2442023-10-30T13:03:19ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232023-10-012910.1177/10760296231208440Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” RegistryJuan José Cerezo Manchado MD, PhD0Teodoro Iturbe Hernández MD, PhD1María del Carmen Martínez Pacheco MSc, RN2Ignacio Gil Ortega MD, PhD3Desirée Campoy MD4Tania Canals Pernas MD5Laia Martinez Serra MD6Katia Jessica Flores Aparco MD7Cesar Andres Velasquez Escandon MD8Luis García de Guadiana-Romualdo MD, PhD9Antonio Martinez Frances MD10Pavel Olivera MD11 Department of Hematology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain Department of Hematology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain Department of Teaching and Research, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain Department of Cardiology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain Thrombosis and Hemostasis Unit, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain Departament of Hematology, , Reus, Spain Department of Hematology, University Hospital Sant Joan de Reus, Tarragona, Spain Department of Hematology, General University Hospital of Catalonia, Barcelona, Spain Department of Hematology, Fundación Sanitària Mollet, Barcelona, Spain Laboratory Medicine Department, Hospital Universitario Santa Lucía, Cartagena, Spain Department of Hematology, Hospital Clínico Universitario Santa Lucía, Cartagena, Spain Thrombosis and Hemostasis Unit, Department of Hematology, Vall d'Hebron University Hospital, Barcelona, SpainObjective To assess the impact of new-onset atrial fibrillation (AF) on patients hospitalized with coronavirus disease 2019 (COVID-19). Methods Multicenter and retrospective study that included subjects >55 years hospitalized with COVID-19 from March to October 2020 in Spanish hospitals. Patients were divided into 3 groups (no AF, new-onset AF, and preexisting AF) and followed-up to 90 days. Results A total of 668 patients were included, of whom 162 (24.3%) had no AF, 107 (16.0%) new-onset AF and 399 (59.7%) preexisting AF. Compared to patients without AF, those patients with new-onset AF were older and had more comorbidities, but without differences with preexisting AF. During hospitalization, in the univariate analysis, compared to patients without AF, major bleeding and cardiovascular mortality were more frequent in patients with new-onset AF (10.3% vs 0.6%; P < .001; 2.8% vs 0.6%; P = .025, respectively), with a trend toward more stroke (1.9% vs 0%; P = .085). Outcomes were similar between AF groups, but the length of stay was greater in preexisting AF patients. Among patients with new-onset AF taking reduced doses of anticoagulant treatment was associated with higher risks of stroke and major bleeding. Conclusions In COVID-19 hospitalized patients, new-onset AF may be associated with worse outcomes, but influenced by the dose of anticoagulants.https://doi.org/10.1177/10760296231208440 |
| spellingShingle | Juan José Cerezo Manchado MD, PhD Teodoro Iturbe Hernández MD, PhD María del Carmen Martínez Pacheco MSc, RN Ignacio Gil Ortega MD, PhD Desirée Campoy MD Tania Canals Pernas MD Laia Martinez Serra MD Katia Jessica Flores Aparco MD Cesar Andres Velasquez Escandon MD Luis García de Guadiana-Romualdo MD, PhD Antonio Martinez Frances MD Pavel Olivera MD Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry Clinical and Applied Thrombosis/Hemostasis |
| title | Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry |
| title_full | Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry |
| title_fullStr | Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry |
| title_full_unstemmed | Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry |
| title_short | Impact of New Onset Atrial Fibrillation in Hospitalized Patients with COVID-19. Results of the “ACO-VID” Registry |
| title_sort | impact of new onset atrial fibrillation in hospitalized patients with covid 19 results of the aco vid registry |
| url | https://doi.org/10.1177/10760296231208440 |
| work_keys_str_mv | AT juanjosecerezomanchadomdphd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT teodoroiturbehernandezmdphd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT mariadelcarmenmartinezpachecomscrn impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT ignaciogilortegamdphd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT desireecampoymd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT taniacanalspernasmd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT laiamartinezserramd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT katiajessicafloresaparcomd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT cesarandresvelasquezescandonmd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT luisgarciadeguadianaromualdomdphd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT antoniomartinezfrancesmd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry AT paveloliveramd impactofnewonsetatrialfibrillationinhospitalizedpatientswithcovid19resultsoftheacovidregistry |